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Received 9 June 2017; revised 12 July 2017; accepted 18 July 2017Abstract Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect
sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels
detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical
recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-
specificmembrane antigen (PSMA), and F-18 fluciclovine. Review of the literature generally favors PSMA-
based agents for the detection of recurrence as a function of lowPSA levels. Positive gallium68/F-18PSMA
positron emission tomography/computed tomography scans detectedpotential sites of recurrence in amedian
51.5% of patients when PSA level is b1.0 ng/mL, 74% of patients when PSA level is 1.0 to 2.0 ng/mL, and
90.5% of patients when PSA level is N2.0 ng/mL. Review of carbon 11/fludeoxyglucose 18 (F-18) choline
and F-18 fluciclovine data commonly demonstrated lower detection rates for each respective PSA cohort,
although with some important caveats, despite having similar operational characteristics to PSMA-based
imaging. Sensitive pcPET imaging has provided new insight into the early patterns of disease spread, which
has prompted judicious reconsideration of additional local therapy after either prostatectomy, definitive
radiation therapy, or postprostatectomy radiation therapy. This review discusses the literature, clinical utility,
availability, and fundamental understanding of pcPET imaging needed to improve clinical practice.
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Prostate cancer remains 1 of the most common
malignancies affecting men worldwide.1,2 Prostate cancer
recurrence following primary treatment is usually signaled
by a rising serum prostate-specific antigen (PSA) level,
which can be quite anxiety-provoking for patients and
clinicians.3-5 Fortunately, advances in prostate cancer–
specific positron emission tomography (pcPET) have
demonstrated new insights into patterns of disease
recurrence.6-8 Emerging pcPET radiotracers including
carbon 11 (C-11) choline, gallium 68 (Ga-68) prostate
specific membrane antigen (PSMA), C-11 acetate, and
18F-fluorocyclobutane-1-carboxylic acid fluciclovine
(FACBC) provide opportunities to localize prostate cancer
recurrence at an earlier state in the disease course when the
PSA level is low, to inform medical decision-making, and
to study PET-directed local therapy.9-13
In anticipation of increased use and availability of
pcPET radiotracers, a critical review of the following is of
interest: (1) fundamentals of PET; (2) current systematic
reviews and meta-analyses of commonly used pcPET
radiotracers; (3) comparative studies evaluating pcPET
radiotracers; (4) US Food and Drug Administration (FDA)
approval and availability; and (5) future directions of
pcPET technology in the management of prostate cancer.
We limit the scope of our discussion to pcPET radiotracers
that image both soft tissue and bone and do not address
other novel methods such as F-18 sodium fluoride PET or
the use of whole body magnetic resonance imaging (MRI).Methods and materials
A comprehensive literature search was performed using
electronic databases, including: MEDLINE, EMBASE,
PubMed, ScienceDirect, Web of Science, Cochrane
Library, and Google Scholar. Search keywords included,
but were not limited to: prostate, prostate cancer, prostate
malignancy, prostate recurrence, recurrent prostate
cancer, biochemical recurrence, positron emission
tomography, PET, prostate specific membrane antigen,
PSMA, choline, C-11 or F-18 choline PET, C-11 acetate
PET, fluciclovine, FACBC, and Axumin. AdditionalTable 1 Properties of important prostate cancer–specific positron
Isotope Half-life (m
Carbon 11 (11C) 20.3
Gallium 68 (68Ga) 67.7
Fluorine 18 (18F) 109.8
Copper 64 (64Cu) 762.1articles were identified by searching bibliographies of
relevant literature.Discussion
Fundamentals of PETPET is a type of functional imaging technique used to
localize metabolic processes. A radionuclide produced
from either a cyclotron or a generator is attached to a
biologically active molecule forming a PET radiotracer.
The PET radiotracer is then introduced into the patient by
injection, ingestion, or inhalation. In modern practice, the
functional information from PET is almost always
acquired simultaneously with anatomic information
provided via computed tomography (CT) scanning or MRI.
Once the PET radiotracer is administered, the patient is
positioned so that detectors can register incident gamma rays,
2 511 keV photons traveling in opposite directions, produced
as the radionuclide decays resulting in an annihilation event
from a positron combining with an electron after traversing a
short distance. The detector’s electronics are synced in such a
way that the 2 photons emitted are detected on opposite sides
and are called coincident and therefore must have originated
from the same annihilation event. These coincident
projections are assigned to a line of response and are then
reconstructed using standard tomographic techniques to
identify the location of the annihilation event. By using
modern “time of flight” information in PET image
reconstruction with very fast scintillators, the origin of the
annihilation event along the line of response is detected with
improved accuracy.14 More recent advancements in PET
imaging and spatial resolution have been further improved by
the use of iterative reconstruction algorithms such as the
Ordered Subsets Expectation Maximization and Bayesian
penalized-likelihood reconstruction algorithms.15 Newer
reconstruction algorithms have mean standardized uptake
value levels 2 to 3 times higher than conventional Ordered
Subsets ExpectationMaximization technology, which should
be considered when comparing studies of intergenerational
scanners.16 Properties of important pcPET radiotracers are
shown in Table 1.17emission tomography radiotracers
in) Production method
Cyclotron
Generator/cyclotron
Cyclotron
Cyclotron
Figure 1 Carbon 11 (C-11) choline positron emission tomography/computed tomography scan of a 75-year-old man status post radical
prostatectomy for prebiopsy prostate-specific antigen (PSA) 5.3 ng/mL, Gleason 8, pT2c,N0,M0, R0 resection who experienced a rising
PSA postoperatively to 0.55 ng/mL and was treated with salvage prostatic fossa only radiation therapy in 7 months later. PSA nadir after
salvage radiation therapy was 0.7 ng/mL. PSA rose quickly to 5.2 ng/mL and patient was referred for C-11 choline (A), which showed a
choline-avid right external iliac lymph node. After 4 months of chemohormonal therapy with 6 cycles of docetaxel and 4 months of
leuprolide acetate, the patient presented for repeat C-11 choline at which time PSA was b0.10 ng/mL (B). The patient then received a
course of concurrent androgen suppression and consolidative radiation therapy to the pelvic lymph nodes, including simultaneous
integrated boost to the prechemohormonal prostate cancer–specific positron emission tomography avid lymph node, with radiation
portals abutting his previously irradiated prostatic fossa. The patient’s PSA remains undetectable (b0.10 ng/mL) with no evidence of
disease on follow-up imaging 2 years posttreatment.
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uniquely. Unlike standard F-18 PET scans, which are
usually imaged starting at the head and scan toward the
feet, pcPET scans typically image the pelvis first. ImagingFigure 2 Prostate-specific membrane antigen (PSMA) structure w
substrate recognition site that are combined with a radioisotope to for
radiotracers as well as first- (G1) and second-generation (G2) F-18 PS
currently being investigated have also been included. ProstaScint targis initiated 3 to 5 minutes after radiotracer administration
and scanning begins at the mid-thigh and proceeds to the
base of skull. This is done primarily to minimize urinary
tract contamination, but also because of the short half-lifeith common PSMA small-molecule inhibitors that target the
m a clinically useful pcPET radiotracer. Common Ga-68 PSMA
MA radiotracers are shown. Promising experimental radiotracers
ets the short intracellular domain.
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the primary reason pcPET protocols are performed in this
manner, including those involving radiotracers with longer
half-lives such as F-18 fluciclovine.
Background for choline, PSMA, and fluciclovine
This review will focus on 3 PET radiotracers of interest:
C-11/F-18 choline, Ga-68/F-18 PSMA, and F-18 fluciclovine.
Choline metabolism has been shown to be altered in
prostate cancer cells. Increased levels of choline com-
pounds concentrate preferentially in human prostate
cancer cells derived from metastases.18 Alteration of
choline metabolites within the cancer cell relates to choline
transport, incorporation, and utilization within the
cell.19-21 Preclinical data conflict on the theory of
augmented choline use by the cell because of increased
cell membrane synthesis and proliferation.18,22,23 Multiple
metabolomic studies on prostate cancer have shown
permutations in choline metabolism not related to cell
membranogenesis23; however, it is well accepted that
choline is used via a 3-step process known as the Kennedy
pathway for the de novo synthesis of phosphatidylcholine,
which is an essential component of the cell membrane.24
Preclinical data have shown that there is an increase in
the expression of choline transporters and an increase
in the choline transport rate in malignant prostate cells
when compared with normal prostate tissues. 25
Interestingly, preclinical data have also shown that
treatment of prostate cancer cells leads to changes
in energetic metabolism and choline metabolism.26
This notion is consistent with what experiencedTable 2 Summary of sensitivity and specificity of meta-analyses e
Systematic review and meta-analysis No. of studies No. of pati
PSMA
Perera10 N = 16 N = 1309
Choline
Fanti54 N = 12 N = 1270
Evangelista55 N = 19 N = 1555
Umbehr56 N = 12 N = 1055
Shen57
(bone metastases)
N = 9 N = 423
Fluciclovine
Ren59 N = 6 N = 251
CI, confidence interval; CT, computed tomography; PET, positron emission
a Meta-analysis did not include 2 recent studies evaluating operational ch
than reported.centers have observed after administration of systemic
therapy to patients with C-11/F-18 choline PET-positive
lymph node(s), wherein the nodes are no longer
choline-avid (Fig 1).
PSMA is highly overexpressed in prostate cancer cells
as a transmembrane protein.27 PSMA is a folate hydrolase
cell surface glycoprotein expressed in a number of
different tissue types, including other cancers, but benign
processes as well. Before malignant transformation has
occurred, PSMA is localized to the cytoplasm and
apical side of the prostate epithelium that lines prostatic
ducts.28 The function of cytoplasmic PSMA is not fully
understood; however, as malignant transformation occurs,
PSMA is transferred to the luminal surface of the prostatic
ducts. 28 PSMA expression has been shown to be
widespread in most prostate tumors even when PSA
staining is negative or weak. 29 Increased PSMA
expression has also been observed when the cell becomes
castrate-resistant.30 As a result, PSMA has emerged as 1 of
the most favorable targets for PET imaging. Prostate
cancer PSMA overexpression has been shown to be 100-
to 1000-fold that of normal tissue expression; furthermore,
PSMA expression may increase as tumor grade and
castrate resistance increases.31,32 PSMA is hypothesized
to have a transport function because it internalizes ligands
similar to J591, a monoclonal antibody that targets the
extracellular domain. In general, targeted antibodies
have presented challenges as diagnostic radiopharmaceu-
ticals with their long circulating half-life and resultant
high nonspecific background-to-tumor noise. Consequent-
ly, the more recent focus of PSMA radiopharmaceutical
development has focused on small-molecule inhibitorsvaluating PSMA, choline, and fluciclovine PET/CT
ents Sensitivity
(per lesion)
(95% CI)
Specificity
(per lesion)
(95% CI)
Sensitivity
(per patient)
(95% CI)
Specificity
(per patient)
(95% CI)
80%
(66-89)
97%
(92-99)
86%
(37-98)
86%
(3-100)
89%
(83-93)
89%
(73-96)
86%
(83-88)
93%
(90-95)
90%
(74-97)
95%
(92-97)
85%
(79-89)
88%
(73-95)
83%
(81-85)
95%
(94-97)
87%
(79-93)
97%
(93-99)
87%
(80-92)
66%
(56-75) a
tomography; PSMA, prostate-specific membrane antigen.
aracteristics for F-18 fluciclovine specificity. Specificity may be higher
Figure 3 Summary of data evaluating pcPET detection rates as a function of PSA. All patients included in the analysis had biochemical
recurrence. General trend favors PSMA across all PSA levels. FACBC, 18F-fluorocyclobutane-1-carboxylic acid fluciclovine. Other
abbreviations as in Fig 1.
Study PET
Radiotracer
% of
Patients
with BCR
% of Patients with Positive PET/CT
PSA b1.0 PSA 1.0-2.0 PSA N2.0
Choline
Mitchell65 C-11 Choline 100% (176/176) 44% (15/34) 67% (21/31) 86% (96/111)
Giovacchini81 C-11 Choline 100% (358/358) 19% (27/141) 46% (39/85) 72% (95/132)
Richter82 C-11 Choline 100% (73/73) 7% (1/15) 46% (6/13) 80% (36/45)
Krause83 C-11 Choline 100% (63/63) 36% (8/22) 43% (3/7) 71% (24/34)
Castellucci84 C-11 Choline 100% (190/190) 19% (10/51) 25% (10/39) 54% (54/100)
Nanni66 C-11 Choline 100% (89/89) 14% (4/28) 29% (8/28) 55% (18/33)
Schwenck69 C-11 Choline 100% (101/101) 44% (8/18) 81% (21/26) 89% (51/57)
Cimitan85 F-18 Choline 100% (1000/1000) 31% (66/211) 43% (66/153) 81% (513/636)
Schillaci86 F-18 Choline 100% (49/49) 20% (2/10) 56% (5/9) 83% (25/30)
Morigi67 F-18Methchol 100% (38/38) 13% (2/16) 36% (5/14) 63% (5/8)
PSMA
Schwenck69 Ga-68 PSMA 100% (101/101) 61% (11/18) 76% (20/26) 93% (53/57)
Morigi67 Ga-68 PSMA 100% (38/38) 50% (8/16) 71% (10/14) 88% (7/8)
Afshar-Oromieh87 Ga-68 PSMA 100% (319/319) 53% (27/51) 72% (28/39) 92% (204/221)
Eiber88 Ga-68 PSMA 100% (248/248) 67% (35/52) 93% (67/72) 97% (120/124)
Bluemel89 Ga-68 PSMA 100% (32/32) 29% (4/14) 46% (5/11) 71% (5/7)
Verburg90 Ga-68 PSMA 100% (155/155) 44% (12/27) 79% (15/19) 89% (97/109)
Fluciclovine
Nanni66 F-18 FACBC 100% (89/89) 21% (6/28) 46% (13/28) 55% (18/33)
Odewole63 F-18 FACBC 100% (53/53) 38% (3/8) 78% (7/9) 86% (31/36)
Bach-Gansmo91 F-18 FACBC 100% (596/596) 41% (53/128) 58% (N?) 75-85% (N?)
Schuster62 F-18 FACBC 100% (93/93) 72% (N?)
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Eder et al first described the most commonly used PSMA
inhibitor in PET imaging, Ga-68 PSMA-HBED-CC,
also known as Ga-68 PSMA-11, which also is
internalized and accumulates in high levels even in small
metastases.28,33There appears to be growing interest in developing an
18-F–labeled PSMA agent. Some experts argue that it
would offer advantages with respect to availability,
production amount, and image resolution. This approach
was first explored at Johns Hopkins University where F-18
DCFBC, the first-generation F-18 PSMA radiotracer, was
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use in Australia and New Zealand.34,35 Since the
development of F-18 DCFBC, second-generation tracers
such as F-18 DCFPyL have been developed.36 Currently,
there are a number of groups working to develop the most
clinically useful next-generation F-18–labeled PSMA
radiotracer.37-42 PSMA’s unique expression differential
between cancer and normal cells coupled with its large
extracellular domain provides an excellent target for
imaging, but also for therapeutics such as theranostic
applications with lutetium 177 PSMA. Less than 10% of
prostate cancers have no uptake on PSMA PET.43
Additionally, the short half-life of Ga-68 (68 minutes)
results in low radiation exposure to patients. Furthermore,
the agent is rapidly cleared from nontarget tissue.
On average, patients receive 3.0 mSv from the PET
component of 150 MBq of Ga-68-PSMA-11, which is
lower than most other pcPET agents such as C-11 and 18-F
choline scans.44,45
Fluciclovine is a synthetic amino acid, and an analog of
L-leucine, which is preferentially taken up by prostate
cancer cells and gliomas via specialized amino acid
transporters, namely alanine-serine-cysteine transporter 2
(ASCT2) and LAT-1. 46-50 Its chemical name is
anti-1-amino-3-FACBC, and is commonly known by its
trade name Axumin. Amino acid transporters such as
ASCT2 play a critical role in amino acid metabolism in
prostate cancer cells. ASCT2 is an important transporter of
glutamine, which is known to be an essential tumor
nutrient and has been implicated in cancer signaling
pathways.51,52 Fluciclovine is predominantly transported
by ASCT2 and transports in a manner similar to
glutamine.53 Unlike glutamine, however, 18-F fluciclovine
does not undergo additional metabolism in the cell, which
lends to its intracellular accumulation particularly in prostate
cancer cells and at major sites of amino acid metabolism
such as the liver and pancreas.54
Additional pcPET radiotracers used in prostate cancer
imaging have been developed as previously noted. These
include C-11 acetate and F-18 sodium fluoride. In
addition, F-18 PET may be useful in imaging prostate
cancer patients who have developed dedifferentiated
neuroendocrine tumors of the prostate,55 which conversely
may not image well using these pcPET agents.
Operational characteristics of PET radiotracers
In recent years, numerous systematic reviews and
meta-analyses have been published evaluating the pooled
operational characteristics of various pcPET radiotracers
in the setting of prostate cancer recurrence (Table 2).
These reports are often analyzed on a per-patient or
per-lesion basis. Caution should be exercised in interpreting
sensitivities and specificities because a comparative gold
standard such as histologic confirmation is not always
available. The focus of this review is recurrent disease;consequently, operational characteristics are emphasized in
the setting of biochemical recurrence after definitive
treatment. The use of these pcPET agents in initial staging,
response to therapy, and radiation therapy planning are of
great interest but beyond the scope of this review. Ga-68
PSMAwas recently evaluated by Perera et al, in which 16
articles including 1309 patients were evaluated.10 When
evaluating on a per-patient basis, the summary sensitivity
and specificity were identical at 86%. When analyzed on
a per-lesion basis, summary sensitivity was 80% and
specificity was 97%. Additionally, it was noted that
patients with biochemical recurrence had increasingly
positive Ga-68 PSMA PET scans as the pre-PET PSA
increased. They found that 58% were positive at a
pre-PET PSA of 0.2 to 1 ng/mL, which increased to 76%
with a PSA of 1 to 2 ng/mL and further increased to 95% for
PSA N2 ng/mL.
C-11 choline was also recently evaluated by Fanti et al,
specifically looking at its ability to detect sites of
recurrence in the setting of biochemical recurrence after
definitive treatment.56 There were 12 studies including
1270 patients to derive a pooled sensitivity and specificity
of 89%. This was similar to previously published
meta-analyses by Evangelista et al, Umbehr et al, and
Shen et al,57-59 although these reports included both C-11
and F-18 choline studies. Fanti et al highlight the accuracy
of C-11 choline PET at different sites of recurrence,
reporting a decreased pooled sensitivity of 61% for
detection of local recurrence. This result is consistent
with comparative studies that have shown multiparametric
MRI with endorectal coil to be superior to C-11 choline for
the detection of local recurrence, whereas C-11 choline
PET/CT was shown to be superior to MRI for pelvic
lymph node metastases and equal with respect to bone
metastases.60
F-18 fluciclovine was evaluated by Ren et al and
included 6 studies including 251 patients with biochemical
recurrence.61 The pooled sensitivity and specificity on a
per-patient analysis was 87% and 66%, respectively;
however, caution should be exercised when interpreting
the specificity in this meta-analysis. Two recent important
papers evaluating the operational characteristics of F-18
fluciclovine were not included in this analysis. Schuster et
al reported specificities of 40% and 97% for prostate bed
and extraprostatic lesions, respectively.62 Odewole et al
similarly demonstrated specificities of 56% and 100% for
prostate bed and extraprostatic lesions, respectively.63
These data indicate that the specificities may be higher
than the meta-analysis suggests, particularly for extrapro-
static disease.
Important factors to consider when interpreting
operational characteristics of various pcPET radiotracers
include the reference standard used to establish positive
and negative proof, particularly with respect to extrapro-
static disease, because these sites can be challenging to
obtain histologic confirmation. Furthermore, whether the
Figure 4 These are the locations of prostate cancer-specific PET scanners across the United States as of 2017. Abbreviations as in Fig 3.
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provides additional insight into the interpretation of data.
For example, many studies relied on histologic confirma-
tion per-patient for positivity of extraprostatic disease,
given it would be impractical to sample every PET avid
site, whereas studies that used a per-lesion analysis often
used a nonhistologic method of disease confirmation,
which is subject to study examination bias.64
Detection rates as a function of PSA
PSA is routinely followed in prostate cancer patients
after definitive treatment; however, the optimal timing of
pcPET imaging is often debated amongst providers in the
setting of a rising PSA after definitive treatment. Data
regarding detection rates as a function of PSA are
summarized in Fig 3. Reviews of 10 choline, 6 PSMA,
and 4 fluciclovine studies evaluating detection rates as afunction of PSA are shown. The median percentage of
patients with positive pcPET scans is shown as the bolded
number over each histogram cluster. The general trend
suggests Ga-68 PSMA is superior to both C-11/F-18
choline and F-18 fluciclovine in detecting recurrence at
PSA levels b2.0 ng/mL.
There are important caveats to this comparative review,
however. First, the fluciclovine data are limited by few
data points. Second, the dose of radiotracer varies greatly
between studies and consequently effects sensitivity,
specificity, and detection rates. For example, in the
study by Mitchell et al, in which detection rates were
relatively high, the C-11 choline dose ranged from 555 to
740 MBq.65 This dose was significantly greater than the
choline dose given in prospective comparative studies that
showed lower choline PET detection rates, which often
used 3.4 to 3.5 MBq/kg.66,67 For an 80-kg patient, this
computes to 280 MBq, essentially half the dose used in the
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such as Ga-68 versus F-18 PSMA, and the use of advanced
iterative reconstruction algorithms will inevitably influence
detection rates in the future, which are important details not
always addressed in related studies. Nevertheless, the
general trend of these data presented in Fig 3 suggests
superiority with PSMAparticularly at PSA levelsb1 ng/mL.
Prospective studies comparing PSMA to choline and/or
fluciclovine PET/CT are currently under way.
Comparative investigations of PET radiotracers
A prospective study by Morigi et al compared Ga-68
PSMA with F-18 fluoromethylcholine.67 The findings
from this study were that Ga-68 PSMA was better than
F-18 fluoromethylcholine in patients with biochemical
failure. It should be noted, however, that this study used
low administered choline doses (3.5 MBq/kg) and a
slightly different radioisotope, F-18 fluoromethylcholine,
as opposed to C-11 choline. Additional data comparing
PSMA to choline come from retrospective series.
Afshar-Oromieh et al evaluated 37 patients with biochem-
ical recurrence that underwent scans with both F-18
fluoromethylcholine and Ga-68 PSMA PET/CT within
30 days of 1 another.68 The authors concluded that
PSMA offered a higher detection rate, higher maximum
standardized uptake value, and higher tumor-to-back-
ground ratio when compared with the F-18 fluoromethyl-
choline scan. Schwenck et al retrospectively compared
Ga-68 PSMA-11 with C-11 choline69 and demonstrated a
higher detection rate with PSMA. Interestingly, however,
of the 67 patients with biochemical recurrence, 458 lymph
node metastases were detected. Although 39% were
exclusively identified with Ga-68 PSMA, there were 6%
identified with C-11 choline only, and the majority (55%)
were identified by both. The advantage of PSMA, and the
clinical situation in which the majority of PSMA-only
detection took place, was in patients presenting with PSA
levels b1 ng/mL.
Comparisons between F-18 FACBC and C-11 choline
have largely been undertaken by Nanni et al. Before 2016,
3 preliminary studies comparing these 2 imaging modal-
ities in patients with biochemical recurrence were
published.70-72 These studies reported favorable detection
rates for fluciclovine compared with choline and provided
background for the publication of their prospective trial.66
The authors showed that, in patients with biochemical
relapse after prostatectomy, F-18 FACBC had higher
sensitivity and specificity compared with C-11 choline
(37% and 67% vs 32% and 40%). They emphasized that
F-18 FACBC had better true-positive findings at lower
PSA levels (b1 ng/mL) with 6/28 (21%) patients with F-18
FACBC versus 4/28 (14%) patients with C-11 choline. A
major limitation of this trial, and a limitation of many
imaging studies evaluating operational characteristics, is
the use of a suboptimal reference standard. The standard ofreference in this particular study was reevaluation of the
clinical and imaging history after following patients for an
average of 1 year. In some cases, this meant histologic
confirmation including 31% (4/13) of patients with
positive local relapse, 15% (4/26) of patients with positive
lymph nodes, and 0% (0/7) of patients with positive bone
lesions. For most cases, however, the standard of reference
was by repeat imaging or PSA trend after therapy.
Furthermore, a low choline dose (3.4 MBq/kg) was
administered, which may limit the study’s generalizability
particularly for centers that use higher choline doses.
There have been no direct comparisons between
fluciclovine and Ga-68/F-18 PSMA to date. Schuster
et al prospectively evaluated patients with biochemical
recurrence comparing F-18 FACBC against indium 111
capromab pendetide (ProstaScint), a radiolabeled mono-
clonal antibody that binds to PSMA.62 This study showed
FACBC performed better than ProstaScint, demonstrating
FACBC’s superiority in detecting more prostatic and
extraprostatic disease and effectively upstaging 25% of
patients. A major strength of this study was the high
incidence of pathologic confirmation of true positives, with
96% (74/77) of index lesions histologically confirmed
including 55 prostate bed and 22 extraprostatic lesions.
Availability and FDA approval
Currently there are 2 pcPET radiotracers that have
gained FDA approval in the United States for the
indication of identifying recurrent prostate cancer. C-11
choline received FDA approval on September 12, 2012,
for the indication of PET imaging of patients with
suspected prostate cancer recurrence.73 F-18 FACBC
received FDA approval on May 27, 2016, for prostate
cancer patients with suspected prostate cancer recurrence
based on elevated PSA levels following prior treatment.74
Ga-68 PSMA has not yet received FDA approval.
ProstaScint, indium-111 capromab pendetide, has gained
FDA approval for its use in the evaluation of patients with
newly diagnosed, biopsy-proven prostate cancer thought
to be clinically localized but high risk for pelvic lymph
node metastasis. Given the growing body of literature
regarding the clinical utility of choline, fluciclovine, and
PSMA, availability around the United States is rapidly
expanding (Fig 4). Sites that provide choline scans are
mostly C-11. Exceptions include the University of
Michigan and The Queen’s Medical Center in Honolulu,
Hawaii, both of which offer F-18 choline scans. Sites that
provide PSMA scans are mostly Ga-68 except for Johns
Hopkins University and University of Wisconsin, both of
which are evaluating F-18 PSMA scans.
In many parts of Europe, Asia, and Australia, pcPET
radiotracers have made their way into widespread clinical
practice. Some have argued that the current FDA
regulation of PET radiotracers has been too prohibitive
and stifling to the innovative process. Such limitations are
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Europe and Australia, where much of the innovation and
data in pcPET radiotracers have been generated.Widespread
international availability has led to multi-institutional
prospectively controlled trials that accrue quickly and, in
turn, are rapidly advancing the science of functional
imaging. As a result, robust data are forthcoming and
essential to determine how best to use this technology.Clinical application of prostate cancer–specific
PET imaging
Patients with a rising PSA after definitive therapy often
ask the clinically relevant question, “Where is the origin of
my rising PSA?” Before the advent of widespread clinical
use of pcPET radiotracers and multiparametric MRI,
clinicians relied on suboptimal tools, primarily bone scans
and CT scans, to explore the answer to this question.
As shown in Fig 3, pcPET radiotracers are able to detect
sites of recurrence when the PSA level is low, even PSA
levels b1.0 ng/mL. By comparison, bone scans detect
osseous metastases at a median PSA level of 40 ng/mL.75
Abuzallouf et al reviewed 23 studies evaluating bone scans
in newly diagnosed cases of prostate cancer and showed
osseous detection rates of 2.3% for PSA b10 ng/mL, 5.3%
for PSA 10.1 to 19.9 ng/mL, and 16.4% for PSA 20.0 to
49.9 ng/mL.76 In the same review, 25 studies evaluating
CT scans found lymph node metastases in 0% of patients
with PSA b20 ng/mL and 1.1% of patients with
PSA N20 ng/mL. Additional evidence from a prospective
population-based analysis of newly diagnosed prostate cancer
showed CT scan detection rates were b15% for patients with
PSA levels between 4 and 20 ng/mL.77 Based on these poor
positive yields, the overall use of bone scan and CT imaging
has declined in pretreatment evaluation, which has also
translated to limited use in the recurrent setting.78
As pcPET radiotracers improve, identification of the
origin of PSA relapse is occurring at lower PSA levels than
ever before demonstrated. Figure 3 demonstrates that a
median of 51.5% of patients have potential sites of
recurrence detected when the PSA level is b1.0 ng/mL
using Ga-68/F-18 PSMA. The detection rate increases to
74% when PSA rises above 1.0 ng/mL, and surpasses 90%
once the PSA level is N2.0 ng/mL. Similar, albeit lower,
trends are observed with choline- and fluciclovine-based
radiotracers. Sensitive functional imaging has led to
patterns of recurrence studies that provide insight into
how prostate cancer spreads early on in the process of
metastasis in a variety of clinical scenarios including
postprostatectomy, post-definitive radiation therapy,
and postprostatectomy radiation therapy.6-8 Patterns of
recurrence studies, such as these and others, have
prompted further discussion regarding additional local
therapy directed to the at-risk nodal basins or aggressive
metastasis-directed therapy.The era of functional imaging has arrived, and
clinicians around the globe are using this technology to
develop customized radiation therapy plans. In a recent
meta-analysis by Ost et al, metastasis-directed therapy to
regional and distant recurrences included 66% of patients
receiving radiation therapy.11 The authors found that 51%
of patients were progression free 1 to 3 years after salvage
metastasis-directed therapy. Toxicity evaluation revealed
metastasis-directed radiation therapy was well tolerated,
with 8.5% of patients experiencing grade 2 toxicities and 1
case of grade 3 toxicity. Retrospective data coupled with
growing experience using pcPET-directed therapy have
prompted the development of prospective studies (Table
Supplementary Material (PDF); available as supplemen-
tary material online only at www.practicalradonc.org). In
addition to pcPET-directed external beam radiation
therapy, there is also growing experience regarding
theranostic applications; the most commonly discussed
being lutetium 177 PSMA, which is beyond the scope of
this review.ConclusionsBiochemical recurrence in the prostate cancer patient
often presents a therapeutic challenge to the treating
oncologist. Data support early intervention with salvage
radiation therapy after prostatectomy and argues against
prolonged monitoring of detectable postprostatectomy
PSA levels.79,80 Patients in this clinical situation may
still benefit from pcPET imaging to identify the area of
recurrence, even at very low PSA levels. Furthermore,
imaging with both a pcPET scan and a multiparametric
MRI scan can provide complementary insight as to the
location of recurrence. Not all patients presenting to the
treating oncologist fall into this relatively common clinical
scenario of a rising PSA early after prostatectomy,
however. Indeed, some patients present with rising PSA
after definitive radiation therapy, whereas others present
after they have received postprostatectomy radiation
therapy, and others still after a late PSA rise years after
initial surgery. It is within these challenging cases that
pcPET imaging has important clinical utility. Review of
the current literature generally favors PSMA-based
imaging in the setting of biochemical recurrence;
nevertheless, more comparative studies are needed to
further clarify which pcPET radiotracer is most appropri-
ate in each of a variety of clinical presentations. Functional
imaging studies that incorporate genomic profiling may
provide additional insight as to which patients will derive
the greatest benefit from pcPET imaging and which
patients have the most to gain from additional local
therapy. Prospective studies are ongoing to assess the
efficacy of pcPET-directed local therapy in patients with
biochemical failure.
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